Business
Bruker Reports Fourth Quarter and Full Year 2025 Financial Results
Q4-25 revenues of $977.2 million, flat year-over-year (yoy), down ~5% organically Q4-25 GAAP diluted earnings per share (EPS) of $0.10; non-GAAP diluted EPS
About this update from Bruker Corporation
[{"type":"text","content":"\n\nQ4-25 revenues of $977.2 million, flat year-over-year (yoy), down ~5% organically\n\n\n\nQ4-25 GAAP diluted earnings per share (EPS) of $0.10; non-GAAP diluted EPS of $0.59\n\n\n\nFY25 revenues of $3.44 billion, up ~2% yoy, down ~4% organically\n\n\n\nFY25 GAAP diluted loss per share of $(0.15); non-GAAP diluted EPS of $1.83\n\n\n\nBruker initiates FY26 guidance:\n\n\nRevenues of $3.57 to $3.60 billion, up 4% to 5% yoy, with organic growth of 1% to 2%\n\n\n\nNon-GAAP EPS of $2.10 to $2.15, up 15% to 17% yoy, including an ~8% FX headwind\n\n\n\n\n\n\n BILLERICA, Mass.--(BUSINESS WIRE)--\nBruker Corporation (Nasdaq: BRKR) today announced financial results for its fourth quarter and for the full year ended December 31, 2025.\n\n\nFrank H. Laukien, Bruker’s President and CEO, commented: “At the conclusion of a difficult year 2025, with headwinds from academic funding, tariffs and currencies, we are pleased that in the fourth quarter we delivered revenues ahead of our expectations. A recovery in biopharma and industrial research markets in the second half of the year, as well improvements in semiconductor orders enabled our Scientific Instruments segment to achieve a book-to-bill ratio greater than 1.0x for the second quarter in a row, while our BEST segment booked strong multi-year orders.”\n\n\nHe continued: “While our fourth quarter margin recovery progressed well sequentially, it was still lagging our prior guidance. Therefore, we have decided to drive our major cost-savings initiatives beyond the upper end of our previous range, and we are poised to deliver very significant operating margin expansion and double-digit EPS growth in 2026. We expect continued improvements in our markets to drive demand for our differentiated post-genomic discovery, translational and diagnostics solutions. Our FY26 guidance assumes a return to organic revenue growth by the second quarter, with LSD organic growth for the full year.”\n\n\nFourth Quarter 2025 (Q4-25) Financial Results\n\n\nBruker’s revenues for the fourth quarter of 2025 were $977.2 million, a decrease of 0.2% compared to $979.6 million in the fourth quarter of 2024. In Q4-25, revenues decreased organically by 5.1%, while growth from acquisitions was 0.8%, and foreign currency translation provided a growth tailwind of 4.1%.\n\n\nQ4-25 Bruker Scientific Instruments (BSI) revenues of...